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Context: Stretch of the myometrium promotes its contractility and is believed to contribute to the
control of parturition at term and to the increased risk of preterm birth in multiple pregnancies.
Objective: To determine the effects of the putative oxytocin receptor (OTR) inverse agonist
retosiban on (1) the contractility of human myometrial explants and (2) labor in nonhuman
primates.
Design: Human myometrial biopsies were obtained at planned term cesarean, and explants were
exposed to stretch in the presence and absence of a range of drugs, including retosiban. The in vivo
effects of retosiban were determined in cynomolgus monkeys.
Results: Prolongedmechanical stretch promotedmyometrial extracellular signal-regulated kinase (ERK)
1/2 phosphorylation. Moreover, stretch-induced stimulation of myometrial contractility was prevented
by ERK1/2 inhibitors. Retosiban (10 nM) prevented stretch-induced stimulation of myometrial
contractility and phosphorylation of ERK1/2. Moreover, the inhibitory effect of retosiban on stretch-
induced ERK1/2 phosphorylationwas preventedby coincubationwith a 100-fold excess of apeptideOTR
antagonist, atosiban. Compared with vehicle-treated cynomolgus monkeys, treatment with oral
retosiban (100 to 150 days of gestational age) reduced the risk of spontaneous delivery (hazard
ratio = 0.07, 95% confidence interval 0.01 to 0.60, P = 0.015).
Conclusions: The OTR acts as a uterine mechanosensor, whereby stretch increases myometrial con-
tractility through agonist-free activation of the OTR. Retosiban prevents this through inverse agonism of
theOTRand, invivo, reducedthe likelihoodof spontaneous labor innonhumanprimates.Wehypothesize
that retosiban may be an effective preventative treatment of preterm birth in high-risk multiple
pregnancies, an area of unmet clinical need. (J Clin EndocrinolMetab 103: 1056–1067, 2018)
Multiple gestations (twins and higher order births)comprise 3% to 4% of all births in the United
States (1) but contribute disproportionately to preterm
birth and its related complications. Infant mortality is 4,
12, and 25 times higher in twins, triplets, and quadru-
plets, respectively (2), and these associations are largely
due to an increased risk of spontaneous preterm birth.
Costs of pediatric care in the United States (2005 to 2010)
were $66,000 more following twin birth (compared with
singleton) and $336,000 more for higher multiples (2).
There is a large body of evidence to indicate that in-
creasingmechanical stretch of the myometrium promotes
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its contractility. As well as contributing to the physio-
logical initiation of parturition at term (3), uterine stretch
is also thought to account for the association between
multiple pregnancy and spontaneous preterm birth (4).
Consistent with this hypothesis, other clinical condi-
tions associated with increased mechanical stretch of
the uterine wall in singleton pregnancies, such as poly-
hydramnios, are also associated with an increased risk of
preterm labor (5, 6). However, there is currently no
clearly effective therapeutic approach to women with
multiple pregnancy who are at high risk of spontaneous
preterm birth (7).
The oxytocin receptor (OTR) system plays an im-
portant role in the regulation of myometrial contractil-
ity. OTR levels are tightly regulated during pregnancy,
peaking upon labor onset, followed by a sharp decline in
the postpartum period when the uterus becomes re-
fractory to oxytocin (8). Furthermore, mechanical stretch
of the uterus has been proposed as a major physiological
stimulus regulating the OTR system during pregnancy (9,
10). We previously demonstrated that the stimulatory
effects of mechanical stretch on contractility of human
myometrial explants were inhibited by 1 mM retosiban
(GSK221149A) (11), a nonpeptide, orally active, and
selective OTR antagonist (12). In the current study, we
test the hypotheses that stretch increases myometrial
contractility through agonist-free activation of the OTR
and that this is inhibited by retosiban through inverse
agonism of the OTR. We also sought to determine
whether the drug alters the timing of spontaneous labor
when administered orally to a nonhuman primate.
Materials and Methods
Study subjects and tissue collection
Humanmyometrial sampleswere obtained froma total of 85
nonlaboring womenwith normal term pregnancies, undergoing
routine elective cesarean section. All patients gave their in-
formed, written consent to participate, and the study was ap-
proved by the Cambridge Research Ethics Committee (04/
Q0108/290). The specimens were taken from the upper edge
of the lower uterine segment incision following delivery of the
baby and the placenta. Myometrial samples were placed in
Krebs solution on ice and processed within 10 minutes
of delivery.
Myometrial explant culture and
experimental design
Each myometrial biopsy was cleared of the serosa, fibrous
tissue, and blood vessels, and dissected into eight longitudinal
explants of ;2 to 3 3 8 to 12 mm. The explants were
maintained in culture medium composed of phenol red–free
Dulbecco modified Eagle medium supplemented with 10%
charcoal-stripped fetal bovine serum, 2 mM L-glutamine, and
antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis,
MO). The explants were suspended in culture medium un-
der either low tension (0.6 g mass) or high tension (2.4 g mass)
using the method previously described (11, 13). The explants
were then treated with retosiban (0.1 nM to 1 mM;
GlaxoSmithKline, Stevenage, United Kingdom), atosiban
(10 nM to 1 mM; Bowmed Ibisqus Ltd., Wrenham, United
Kingdom), U0126 (10 mM; Tocris Bioscience, Abingdon,
United Kingdom), SCH772984 (10 mM; Tocris Bioscience), or
vehicle (dimethyl sulfoxide, 0.1% v/v), and incubated in a 5%
CO2 humidified atmosphere at 37°C. Following 20-hour in-
cubation, the explants were transferred to an organ bath for
isometric tension studies or processed for protein analyses. For
inverse agonism studies, explants were incubated with either
10 nM retosiban, 1 mM atosiban, or retosiban with atosiban.
Retosiban exhibits;16-fold greater affinity for the OTR than
atosiban (14); hence, a 100-fold excess of retosiban was used
to determine whether the atosiban could block the effects of
10 nM retosiban.
Isometric tension measurements
Myometrial contractility was studied using the previously
described protocol (15), and all explants were studied under
2 g tension. For analysis of contractility after explant culture,
maximal responses to KCl and oxytocin (measured in grams)
were normalized to strip wet weight (also measured in grams)
to produce a normalized response. The mean normalized
responses of duplicate strips were then calculated. Effects
were expressed as fold change, i.e., the ratio of the mean
normalized responses in the experimental and control con-
ditions from different strips obtained from the same woman.
Negative logarithm of the half-maximal effective concen-
tration (pEC50) values were calculated using analysis of the
area under the curve for each concentration to oxytocin, as
previously described (16). The concentration-dependent ef-
fects of retosiban were studied in myometrial biopsies from
20 different women, and the effects of mitogen-activated
protein kinase kinase (MEK)/extracellular signal-regulated
kinase (ERK) inhibitors were studied in myometrial biopsies
from 10 different women.
Phosphokinase array analysis
Analysis of the phosphorylation profiles of kinases and their
protein substrates was performed using Human Phospho-
Kinase Arrays (R&D Systems, Minneapolis, MN). Myo-
metrial explants (N = 12) were incubated for 20 hours under
0.6 g or 2.4 g with vehicle for 20 hours and then snap frozen in
liquid nitrogen and transferred to 280°C. Protein lysates were
prepared using the FastPrep24 sample disruption system with
Lysing Matrix S tubes (MP Biomedicals, Santa Ana, CA).
Protein concentration was determined by bicinchoninic acid
assay (ThermoFisher Scientific, Waltham, MA), and 500 mg
each tissue lysate was added to preblocked antibody array
membranes for incubation. Membranes were treated with de-
tection antibody cocktail, followed by streptavidin-horseradish
peroxidase as instructed, and signal was detected using en-
hanced chemiluminescence (ECL) on Kodak X-Omat LS X-ray
film (Sigma-Aldrich). ECL detection was performed at multiple
time points to acquire the optimal exposure period for different
antibody targets. Signal intensities were quantified using ImageJ
software (imagej.nih.gov) and calculated as instructed in the
array manufacturer’s protocol.
doi: 10.1210/jc.2017-02195 https://academic.oup.com/jcem 1057
Downloaded from https://academic.oup.com/jcem/article-abstract/103/3/1056/4774927
by University of Cambridge user
on 07 March 2018
Protein phosphorylation and oxytocin analysis by
enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assays (ELISAs) were per-
formed to validate the results obtained from phosphokinase
arrays, in an independent set of myometrial explants subjected
to either 0.6 g or 2.4 g tension for 20 hours and incubated with
retosiban (0.1 nM to 1 mM), atosiban (10 nM to 1 mM), and
10 nM retosiban with 1 mM atosiban or vehicle (N = 33).
The following ELISAs were performed according to the man-
ufacturer’s instructions: DuoSet IC ELISAs (R&D Sys-
tems), phospho-ERK1 (T202/Y204)/ERK2 (T185/Y187), total
b-catenin and phospho–platelet-derived growth factor receptor
b (PDGF Rb), and Simple Step ELISA (Abcam, Cambridge,
United Kingdom) phospho-STAT5A/B (Y694/699) and phospho-
STAT5A (Y694). Oxytocin ELISAswere performed in lysates of
myometrial explants subjected to 0.6 g or 2.4 g tension.
Source of the ELISA kits and their catalog numbers are listed
in Supplemental Table 1.
Western blot analysis
ERK phosphorylation data from tissue ELISAs were con-
firmed by Western blot analysis using the same phospho-ERK1
(T202/Y204) ERK2 (T185/Y187) antibody clone (R&D Sys-
tems). Myometrial explant cultures (20 hours) were performed
with the following treatments: 0.6 g vehicle, 2.4 g vehicle, and
2.4 g with 10 nM retosiban. Frozen tissues were lysed in
radioimmunoprecipitation assay buffer containing protease
inhibitors and phosphatase inhibitor cocktail 1 and 2 (1:100;
Sigma-Aldrich). Protein concentrations were determined by
bicinchoninic acid assay (ThermoFisher Scientific). Twenty
micrograms of protein was loaded into each well and separated
on Any KD Mini-Protean Tris Glycine Precast gels (Bio-Rad,
Hercules, CA). Separated proteins were then transferred onto
polyvinylidene difluoride membranes using the iBlot system
(ThermoFisher Scientific) and blocked with 5% nonfat milk
powder for 1 hour. After washing in Tris-buffered saline con-
taining 0.1% Tween (TBS-T), membranes were incubated in
rabbit anti–phospho-ERK1 (T202/Y204) ERK2 (T185/Y187)
antibody (R&D Systems) at 1 mg/mL overnight at 4°C in TBS-T
containing 2% bovine serum albumin. The membranes were
then washed and incubated with peroxidase-conjugated goat
anti-rabbit (1:2000) inTBS-Twith 2%bovine serum albumin for
2 hours at room temperature and detected by ECL using ECL
Western Blotting Substrate (Pierce, ThermoFisher Scientific) on
Kodak X-Omat LS X-ray film (Sigma-Aldrich). Membranes
were stripped in Restore Western Blot Stripping Buffer (Ther-
moFisher Scientific) and reprobed with mouse anti-ERK1/2
antibody (Cell Signaling Technology, Danvers, MA). Densi-
tometry analysis was performed using ImageJ software.
Total protein levels were determined by Amido Black (Sigma-
Aldrich) staining.
Toxicological experiments on cynomolgus monkeys
All animal studies were ethically reviewed and carried out in
accordance with European Directive 2010/63/EEC and the
GlaxoSmithKline Policy on the Care, Welfare, and Treatment
of Animals. Sufficient purpose-bred cynomolgus monkeys
(Macaca fascicularis) of Chinese/Vietnamese origin were ob-
tained from Nafo Vanny (Vietnam) and Guangdong Scientific
Instruments (China). The female animals were purpose bred and
sexually mature. The females were in the weight range from 2.5
to 6.6 kg at selection for mating and were at least 3 years old.
Sexually mature, untreated males were used for mating only.
Animalswere housed in individual cages, and the environmental
controls were set tomaintain temperaturewithin the range 19°C
to 25°C and relative humidity within the range 30% to 70%
with a ;12-hour light and ;12-hour dark cycle. Each animal
was offered twice daily a commercial pellet diet for primates
(Ssniff P10, Ssniff Spezialdia¨ten, Ferdinand-Gabriel-Weg 16,
59494 Soest, Germany). In addition, the animals received fresh
fruit and bread. Any residual food was removed and estimated
in the morning and afternoon. Tap water was provided ad
libitum via an automatic watering system or bottles.
The data presented in this work are part of a toxicology
study conducted to assess the safety of retosiban, and not all
data and end points are described. The animals were assigned to
dosing groups on day 90 postcoitum using a random table. By
use of this random table, the sequence of pregnant animals
assigned to treatment groups was predetermined. Pregnant
animals were selected to the study based on day 90 postcoitum
ultrasound to confirm the pregnancy, absence of any signs of ill
health of the mother or the fetus, within the normal range
gestational body weight gain, and fetal size within normal
range. Retosiban or vehicle [1% (w/v) aqueous methylcellulose
with 0.1% (w/v) Tween 80] was given by oral administration
(4 mL/kg/d) once per day to the pregnant animals between day
100and150ofgestation (0.6and0.9gestation)at either100mg/kg/d
or 300 mg/kg/d. The average duration of cynomolgus gestation
in a primate facility is 160 days (17).
Each of the three groups (vehicle, 100 mg/kg/d, or 300 mg/
kg/d) included 18 animals: 12were allowed to progress to labor,
and 6 were delivered by planned cesarean at 1506 1 days. One
of the purposes of planned cesarean section was to allow col-
lection of fetal blood from the umbilical vein to determine the
concentration of retosiban. Maternal blood was also collected
from the anesthetized mother immediately after fetal blood
collection to determine maternal retosiban concentrations. Of
the 18 animals (6 from each group) in which prelabor cesarean
delivery was planned, 2 vehicle control animals delivered
spontaneously and a single retosiban animal (300 mg/kg/d
retosiban) had an emergency cesarean section performed on
gestation day 148 due to signs associatedwith delivery (hunched
posture). In the statistical analysis, this delivery was treated as
spontaneous labor rather than censoring. The remaining 36
monkeys were allowed to deliver their offspring, and gestation
length was calculated. Hence, overall, 38 animals had a
spontaneous delivery, one had an emergency cesarean deliv-
ery for presumed labor, and 15 animals had a planned
prelabor cesarean.
Although we do not present any safety data in the present
paper, a range of endpoints related to the safety of retosiban for
primate pregnancy and offspring health was evaluated. In
pregnant monkeys, clinical signs, ultrasonography, fetal heart
rates, weekly body weight, and food consumption were
assessed. At cesarean delivery, the fetal blood pH, hematocrit,
hemoglobin, blood gas, placental weight and morphology, fetal
weight, external morphology and gross organ morphology, and
microscopic evaluation of kidney and lung were assessed. For
the spontaneously delivered animals, the mother and the off-
spring were evaluated for 6 months, and during this time off-
spring electrocardiogram and neuromuscular development
were assessed at 5 to 6 weeks of age along with body weights
and clinical observations. Infant blood sampling (blood gasses,
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pH, clinical pathology) was conducted at 3months of age. There
were no retosiban-related effects on any of the experimental
endpoints evaluated that precluded the administration of
retosiban to pregnant women. The safety data were reviewed by
both the US Food and Drug Administration and the European
Union European Medicines Agency prior to approval for
human clinical trials of retosiban (NCT02377466,NCT02292771,
and NCT00404768) in the treatment of women presenting in
presumed spontaneous preterm labor, the original indication
for the drug.
Statistical analysis
For human myometrial studies, all experiments were re-
peated in myometrial biopsies from 10 to 20 different women
(represented by N). The data are expressed as fold changes,
ratios were log transformed, and the normality of the dis-
tribution following log transformation was assessed using
Shapiro–Wilk test. For contractility and ELISA experiments,
paired t test or one-way ANOVA followed by Dunnett post
hoc test was performed, and P , 0.05 was considered sig-
nificant. Phosphokinase array experiments were analyzed by
multiple t tests and corrected for false discovery rate using the
Benjamini–Hochberg method (false discovery rate set at 5%).
The primate data were analyzed using time-to-event methods,
as previously described (18). The event was spontaneous de-
livery (or, in a single case, emergency cesarean during labor),
and planned cesarean was treated as censored. Data were
presented using a Kaplan–Meier plot. Modeling was by the Cox
proportional hazards model, and the proportional hazards
assumption was tested using the method of Grambsch and
Therneau (19). Given that visual inspection of the Kaplan–
Meier plot indicated crossing of the curves and that the pro-
portional hazards test was significant, the comparison of the
Kaplan–Meier plot used the Wilcoxon (Breslow) test (20), as
the more conventionally used log–rank test tends to be un-
derpowered in this situation (21). To determine whether the
results were dependent on the specific test used, we also com-
pared the curves using two other tests that are appropriate when
the hazards are nonproportional: the Tarone-Ware and Peto-
Peto-Prentice tests (22, 23).
Results
Prolongedmechanical stretch stimulatesmyometrial
contractility and activates phosphokinase proteins
We initially sought to replicate our previous findings
(11, 24) that prolonged mechanical stretch of human
myometrium stimulates its contractility. Human myo-
metrial biopsies were obtained at the time of planned
cesarean section and divided into multiple explants from
the same woman. Explants were repeatedly washed, and
then pairs of explants from the same woman were in-
cubated under high or low tension for 20 hours and their
contractility subsequently studied in vitro. Incubation
under high tension increased maximal responses to KCl
by 90% and to oxytocin by 80% (P = 0.0003 and P =
0.003, respectively, N = 10; Fig. 1a and 1b; Supplemental
Fig. 1a). The pEC50 to oxytocin (the2log10 of the molar
concentration of the drug required to achieve 50% of the
maximum response) was not affected by myometrial
stretch (Supplemental Fig. 1b).
To examine the phosphorylation events triggered by
prolonged stretch,weused aphosphokinase profiler array to
compare levels of phosphorylated proteins in paired ex-
plants (from 12 additional women) incubated under high or
low tension for 20 hours (Fig. 1c).We identified significantly
increased ERK1/2 (T202/Y204, T185/Y187) phosphory-
lation, decreased b-catenin levels, and decreased phos-
phorylation of PDGFRb (Y751) STAT5A (Y694), STAT5B
(Y699), and STAT5A/B (Y694/Y699) (Padj, 0.05; Fig. 1d).
To validate the phosphokinase array results, we performed
ELISAs in biological replicates (Fig. 1e), i.e., using myo-
metrial biopsies from an additional 10 women, as well as
technical replicates (Supplemental Fig. 2), i.e., using the same
myometrial explants used for arrays. Again, exposure of
explants to high tension for 20 hours significantly altered
ERK1/2 (P , 0.0001) and PDGF Rb (P , 0.0001) phos-
phorylation and b-catenin protein levels (P = 0.002). The
biggest proportional change was in ERK1/2 phosphoryla-
tion, which increased fourfold under high tension. Stretch-
induced phosphorylation of STAT5A (Y694) and STAT5A/
B (Y694/Y699)wasnot replicatedwhenmeasuredbyELISAs,
and we were unable to validate the results of STAT5B
(Y699) due to the lack of a reliable commercially
available antibody for ELISA. Similar findings were also
found in technical replicates of myometrial tissues used
for phosphokinase arrays (Supplemental Fig. 2).
Pharmacological antagonism of MEK–ERK pathway
inhibits stretch-induced myometrial
contractile activity
The functional significance of stretch-induced ERK
activationwas investigated by incubating explants froman
additional 10 women under high or low tension for
20 hours with or without ERK inhibitors. We targeted
ERKactivity using two pharmacological antagonists of the
MEK–ERK signaling pathway: U0126 was used to inhibit
MEK1/2, the upstream kinase of ERK1/2, whereas
SCH772984 is a competitive inhibitor of the ERK1/2
kinase. The effect of stretch on the KCl response was
inhibited by SCH772984 by 36% (P , 0.05; Fig. 2a; Sup-
plemental Fig. 3a), whereas bothU0126 and SCH772984
prevented stretch-mediated increase in oxytocin response
by 37% and 44%, respectively (P, 0.05 and P = 0.002,
respectively; Fig. 2b; Supplemental Fig. 3a). The pEC50
values to oxytocin were not significantly affected by any
of the treatments (Supplemental Fig. 3b).
Concentration dependence of retosiban in
regulating stretch-induced myometrial contractility
We then sought to replicate our previous finding that
1 mM retosiban (11) reduces the effect of prolonged stretch
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and to determine whether this effect was seen with lower,
therapeutically relevant concentrations of the drug. Explants
from the same myometrial biopsy were incubated under
high stretch with retosiban or its vehicle for 20 hours. All
explants were then thoroughly washed to remove the drug,
and their contractility was studied in vitro. Incubation in
retosiban (10 nM, 100 nM, and 1mM) during the period of
mechanical stretch was associated with decreased sub-
sequent maximal responses to KCl (21%, 23%, and 38%,
P = 0.008, P = 0.001, and P = 0.0001, respectively; Fig. 3a;
Supplemental Fig. 4a) and oxytocin (18%, 25%, and 40%,
P = 0.02, P = 0.0005, and P = 0.0001, respectively; Fig. 3b;
Figure 1. Effects of myometrial stretch on maximal contractile responses and activation of signaling proteins. Myometrial explants were incubated
under low (0.6 g) or high (2.4 g) tension in duplicate and the maximal response to (a) KCl (50 mM) and (b) increasing concentrations of oxytocin
(up to 100 nM) determined by isometric tension studies and expressed as fold change from 0.6 g tension. Values shown are mean + standard error,
N = 10. Tissue lysates of explants incubated under low (0.6 g) or high (2.4 g) tension and analyzed by (c, d) phosphokinase arrays and (e) tissue
ELISAs. (c) Representative blots showing the levels of phosphorylation of individual kinases and their protein substrates in 0.6 g or 2.4 g tension
tissues. Black boxes on the arrays correspond to ERK1/2 (T202/Y204, T185/Y187) antibodies. (d) Protein levels of targets significantly altered by
stretch on phosphokinase arrays. Values shown are mean + standard error, N = 12, and were corrected for multiple testing. (e) Phosphokinase array
results were validated in an independent cohort by tissue ELISAs using the same monoclonal antibodies where available. Values shown are mean +
standard error, N = 10. Effect of stretch (2.4 g) on protein levels is expressed as fold change from low tension (0.6 g).
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Supplemental Fig. 4a). The pEC50 ofmyometrial explants to
oxytocin was not significantly affected by retosiban at these
concentrations (Supplemental Fig. 4b).
Effect of retosiban on stretch-induced
phosphokinase proteins
To determine themechanism of action of retosiban, we
exposed explants from an additional 10 women to
20 hours of high tension in the presence of the drug or vehicle
and then analyzed the signaling proteins that we had
identified as regulated by stretch. Both 10 nM and 1 mM
retosiban reduced phosphorylation of ERK1/2 (Fig. 4a
and 4b), by 53% and 62%, respectively (P, 0.0001 and
P = 0.0005). In contrast, retosiban had no effect on
b-catenin protein and phospho–PDGF Rb levels (Fig. 4c
and 4d). Lower concentrations of retosiban (0.1 nM and
1 nM) did not affect stretch-induced ERK1/2 phos-
phorylation (Supplemental Fig. 5).
Figure 2. Effect of MEK1/2 and ERK1/2 inhibitors on the maximal contractile responses to KCl and oxytocin. Myometrial explants were incubated
under high tension (2.4 g) with 10 mM U0126 (MEK1/2 inhibitor), 10 mM SCH772984 (ERK1/2 inhibitor), or vehicle (Veh) in duplicate. (a)
Representative set of traces showing the response to KCl (50 mM) and increasing concentrations of oxytocin (up to 100 nM). The effect of 2.4 g
vehicle, 2.4 g U0126, or 2.4 g SCH772984 on maximal contractile responses to (b) KCl or (c) oxytocin, expressed as fold change from 2.4 g
vehicle. Values shown are mean + standard error, N = 10.
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Comparison of the effects of retosiban and atosiban
on stretch-induced ERK1/2 phosphorylation
We next studied ERK1/2 phosphorylation in myo-
metrial explants incubated under high stretch and compared
the effects of retosiban with atosiban, a structurally un-
related peptide antagonist of the OTR (N = 6 to 13).
Again, stretch-induced ERK1/2 phosphorylation was
significantly inhibited by 10 nM retosiban (P, 0.05) and
Figure 3. Effect of retosiban (Ret) on maximal contractile responses to KCl and oxytocin. Myometrial explants were incubated under high tension
(2.4 g) in the presence of 10 nM, 100 nM, or 1 mM retosiban, or vehicle (dimethyl sulfoxide) in duplicate. (a) Representative set of traces
showing the response to KCl (50 mM) and increasing concentrations of oxytocin (up to 100 nM). The effect of retosiban on maximal contractile
responses to (b) KCl or (c) oxytocin, expressed as fold change from 2.4 g vehicle controls. Values shown are mean + standard error, N = 20.
1062 Aye et al Retosiban Inhibits Myometrial Contractions J Clin Endocrinol Metab, March 2018, 103(3):1056–1067
Downloaded from https://academic.oup.com/jcem/article-abstract/103/3/1056/4774927
by University of Cambridge user
on 07 March 2018
1 mM (P = 0.001) retosiban (Fig. 5a). Interestingly,
atosiban did not inhibit stretch-induced ERK1/2 phos-
phorylation at concentrations up to 1 mM (Fig. 5b).
Atosiban reverses the inhibitory effects of retosiban
on stretch-induced ERK1/2 phosphorylation
To establish whether the inhibitory effect of retosiban
on stretch-induced myometrial contractility was medi-
ated through the OTR, we determined whether this effect
of retosiban could itself be blocked by a 100-fold molar
excess of atosiban. We studied myometrial biopsies from
an additional 20 women. We again observed that pro-
longed stretch of myometrial explants increased ERK1/2
phosphorylation, and that this effect was inhibited by
coincubation in 10 nM retosiban. Atosiban (1 mM) alone
did not significantly alter ERK1/2 phosphorylation in
tissues incubated under low tension (with or without
retosiban) or high tension in the absence of retosiban
(Fig. 5c; Supplemental Fig. 6). However, in explants in-
cubated under high tension, coincubation with atosiban
prevented the inhibitory effects of retosiban on ERK1/2
phosphorylation (P = 0.01) (Fig. 5c).
Mechanical stretch does not affect myometrial
oxytocin levels
To determine whether the effects of stretch on oxy-
tocin receptor activity were associated with changes in
myometrial oxytocin production, we measured oxytocin
levels in myometrial explants incubated under low and
high tension (N = 16). Myometrial oxytocin levels were
not affected by stretch (Supplemental Fig. 7).
Retosiban reduces the risk of spontaneous labor in
cynomolgus monkeys
To establish whether oral retosiban could reduce the risk
of spontaneous labor, we reanalyzed an extensive series of
toxicological experiments performed in a pregnant non-
human primate model, the cynomolgus monkey. The
analytic approach was to use time-to-event analysis to
compare the probability of spontaneous labor, as previously
Figure 4. Retosiban effects on phosphorylated and total protein levels of ERK1/2, b-catenin, and PDGF Rb. Protein levels of tissue lysates of
explants incubated under high tension (2.4 g) with vehicle, 10 nM or 1 mM retosiban. (a) Representative Western blot of phospho- and total
ERK1/2 in tissues under low or high tension vehicle or high tension with 10 nM retosiban. Histograms represent relative protein levels of (b)
phospho-ERK1/2 (T202/Y204, T185/Y187), (c) b-catenin, and (d) phospho–PDGF Rb (Y751). Data are represented as fold change from high
tension vehicle (2.4 g Veh). Values shown are mean + standard error, N = 10.
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described in women (18). The event was spontaneous de-
livery, and prelabor cesarean was treated as censoring.
Animals were exposed to vehicle (n = 18), 100 mg/kg oral
retosiban (n = 18), or 300mg/kg oral retosiban (n = 18), and
the two doses of retosiban were combined into a single
group. AKaplan–Meier plot (Fig. 6a) indicated an excess of
early deliveries in vehicle-treated animals, and there was a
statistically significant difference between the two curves
(P = 0.007). The association remained significant when the
single animal delivered by emergency cesarean was ex-
cluded (P = 0.003). The two doses of retosiban had been
combined into a single group to increase statistical power.
However, when the two doses were analyzed individually,
therewere significant associationswith both 100mg/kg (P=
0.045) and 300 mg/kg (P = 0.026). When all animals de-
livered by cesarean section were excluded, there was still a
significant association with retosiban (P = 0.01).
Analyzing all retosiban-treated animals, the test for
nonproportionality of the hazards across the whole range of
gestational age was significant (P = 0.02). In the earlier
period (i.e., during treatment), the retosiban group had a
reduced risk of spontaneous (hazard ratio = 0.07, 95%
confidence interval 0.01 to 0.60, P = 0.015), whereas there
was no difference in the later period (i.e., after cessation of
the treatment; Fig. 6b). Collectively, the data demonstrate a
reduced risk of early labor among animals while being
treated with the drug, but no difference in the timing of
normal labor after its cessation.
Discussion
We confirm that prolonged stretch of human myome-
trium increases its contractility. This property of uterine
smooth muscle is biologically and clinically relevant as it
is thought to be involved in the physiological control of
parturition at term andmay be a determinant of the much
higher rates of preterm birth observed in multiple preg-
nancies. In the current study, we provide mechanistic
evidence for why stretch has this effect and identify
a therapeutic approach to reverse it. Furthermore, we
provide evidence that oral retosiban prevented early
delivery in a nonhuman primate.
Figure 5. Effect of retosiban, atosiban (Ato), or retosiban with atosiban on ERK1/2 phosphorylation in stretched tissues. Myometrial explants
were incubated under low tension with vehicle, high tension with vehicle, high tension with (a) retosiban (10 nM or 1 mM), or high tension with
(b) atosiban (10 nM or 1 mM). Tissue lysates were examined for ERK1/2 phosphorylation by ELISAs. Data are represented as fold change from low
tension vehicle. Values shown are mean + standard error, N = 6 to 13. (c) Myometrial explants incubated under high tension were treated with
vehicle, 10 nM retosiban, 1 mM atosiban, or 10 nM retosiban and 1 mM atosiban. Tissue lysates were examined for phospho-ERK1/2 (T202/Y204,
T185/Y187) levels by ELISAs. Data are represented as fold change from low tension vehicle. Values shown are mean + standard error, N = 20.
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We show that prolonged stretch of human myometrium
increases phosphorylation of a number of signaling pro-
teins, with the strongest effect being increased phosphor-
ylation of ERK1/2. The functional importance of ERK1/2
phosphorylation is illustrated by the prevention of stretch-
induced contractility by coincubation with two established
inhibitors of the ERK1/2 signaling pathway. In multiple
biological replicates, we have demonstrated that the stim-
ulatory effect of stretch on myometrial contractility is pre-
vented by coincubation in retosiban, an OTR antagonist.
Moreover, retosiban has this effect in low nanomolar
concentrations of the drug,which arewell within the range
obtained therapeutically (25), and the inhibition of stretch-
induced contraction is paralleled by the inhibitionof stretch-
induced phosphorylation of ERK1/2. Finally, the effect of
retosiban on ERK1/2 phosphorylation is itself blocked by a
100-fold molar excess of atosiban, a structurally unrelated
competitive antagonist of the OTR. Collectively, the data
support the hypothesis that myometrial stretch causes
agonist-free activation of the OTR and that retosiban re-
verses this effect through inverse agonism of the same
receptor. Furthermore, it is unlikely that the effects of
retosiban were due to antagonism of endogenous oxytocin
as (1) atosiban had no such effect and (2) there were no
differences in oxytocin levels in tissues incubated under low
or high tension.
Figure 6. Effect of retosiban (100 mg or 300 mg) between 100 and 150 days of gestational age on the timing of spontaneous labor in
the cynomolgus monkey, and model of OTR conformational states under nonstretched and stretched conditions. (a) Time-to-event analysis
treated spontaneous delivery as the event and prelabor cesarean delivery as censoring, and the P value was estimated using the Wilcoxon
(Breslow) test for equality of survivor functions, which does not assume proportional hazards. The result was also statistically significant when
compared using the Tarone-Ware test and the Peto-Peto-Prentice tests (P = 0.02 and 0.01, respectively), which also do not assume proportional
hazards. (b) The hazard ratio for delivery associated with retosiban treatment from 100 to 150 days, splitting the period of analysis at day 151.
The test of the proportional hazards assumption indicated that the hazard of spontaneous delivery associated with being treated by retosiban
varied over the entirety of the experiment (P = 0.02). When we repeated the analysis splitting the data on the day of cessation of treatment with
retosiban (day 151), there was no evidence for nonproportionality of the hazard ratio when the two time periods were analyzed separately: 100
to 151, P = 0.60; 151 to 176, P = 0.53, but the risk of spontaneous labor only differed in relation to treatment group over the period (up to 150
days) when the animals actually had the drug administered. (c) Hypothetical model of OTR conformational states triggered by mechanical stretch.
In nonstretched conditions, oxytocin changes the conformational state of the OTR leading to signal tranduction. This effect can be inhibited by
preventing oxytocin binding to the OTR by antagonists or inverse agonists. Mechanical stretch promotes agonist-free conformational changes in
the OTR, which activate signal transduction. This effect of stretch can be inhibited by inverse agonism of the OTR.
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Three lines of evidence indicate that the effects of stretch
and retosiban are mediated through the OTR. First, the
effects of retosiban were observed in the nanomolar range,
making it unlikely that these were off-target effects of the
drug. Second, ERK1/2 is known to be a key signaling
pathway following OTR activation (26). Third, the effects
of retosiban were blocked by an excess of a structurally
unrelated OTR antagonist. Furthermore, the plausibility of
the hypothesis is supported by other previous studies.
Multiple other studies of myometrium have demonstrated
effects of stretch on the OTR and ERK1/2 (10, 27, 28).
Moreover, stretch-induced receptor activation and reversal
by inverse agonists have previously been described in other
tissues and with other G protein–coupled receptors. For
example, analogous observations have been made in cul-
tured rat myocardiocytes, where mechanical stretch in-
creased ERK1/2 phosphorylation by agonist-free activation
of the AT1 receptor, which was reversed by an orally active
nonpeptide AT1 receptor antagonist (olmesartan) through
an additional inverse agonist property of the drug (29–31).
There are many other examples of mechanosensitive G
protein–coupled receptors (32), in particular a number of
Gq/11-coupled receptors appear to function as mechano-
sensors in smoothmuscle cells (33).Hence, the data support
the concept that the OTR, which is also a Gq/11-coupled
receptor, acts as a uterine mechanosensor in an oxytocin-
independent manner (illustrated in Fig. 6c). We speculate
that this property of the oxytocin receptor is involved in the
physiological initiation of parturition at term.
On the basis of these findings, we speculate that reto-
siban could have utility as a preventative treatment in
multiple pregnancy. The increased risk of spontaneous
preterm birth in twins is thought to be related to stretch-
induced stimulation of myometrial contractility. The cur-
rent data indicate that retosibanmay specifically inhibit this
effect. If so, it is plausible that retosiban could be given as a
preventative treatment, as stretch is also thought to be in-
volved in the control of parturition near term. Hence, it is
plausible that the drug could also reduce the risk of labor if
administered in the period of gestation leading up to term.
This is not a hypothesis that can be tested in women.
However, we reanalyzed an extensive series of toxicological
experiments performed in a nonhuman primate model
(these were a requirement from the Food and Drug Ad-
ministration prior to clinical studies in pregnant women). A
complexity in the approach to that dataset was the fact that
15 of 54 animals were delivered by prelabor, planned ce-
sarean as part of the experimental design.We addressed this
using time-to-event analytic methods that account for
censoring. This allows the animal to be included in the
denominator in the weeks leading up to the day of planned
cesarean. Simply dropping these animals both reduces
statistical power and systematically excludes animals that
did not experience early labor. Using these methods, we
found strong evidence to support the hypothesis that oral
retosiban reduced the risk of early labor. However, these
results should be assessed cautiously as this was a secondary
analysis of data, i.e., determining the effect of retosiban on
the timing of labor was not the primary purpose of the
primate experiments. Moreover, we analyzed the effect of
retosiban on the timing of labor in the last third of preg-
nancy. The rationale is that increased myometrial stretch
might be involved in the association between spontaneous
preterm birth in multiples and the physiological regulation
of the timing of labor at term. Although the primate work
supported our in vitro data, we do not have direct evidence
from animal studies for a protective effect of the drug in the
context of preterm labor and multiple pregnancy.
A Phase 2 clinical trial of intravenous retosiban for the
treatment of spontaneous preterm birth in singleton
pregnancies showed favorable efficacy and safety profile
(25). Unfortunately, Phase 3 trials of the drug for the
treatment of spontaneous preterm labor have recently
been discontinued due to lack of recruitment. This may
reflect the existence of multiple other agents for acute
tocolysis and a generally poor evidence base supporting
better infant outcomes in this context. However, high-
risk multiple pregnancy (e.g., twins with a short cervix or
triplets and higher multiples) is a major area of unmet
clinical need (7). Hence, a possible future approach to
clinical evaluation of this drug would be to treat women
with high-risk multiple pregnancy, potentially focusing
on the gestational ages (24 to 32 weeks) associated with
the highest risks of severe short- and long-term adverse
outcome (34). Such a preventative approach is facilitated
by the fact that the drug can be administered orally.
Finally, unlike many other drugs that control uterine
contractility, such asb2 adrenoceptor agonists or calcium
channel blockers, retosiban does not have widespread
maternal systemic effects, due to its high degree of
specificity for the OTR and the limited role for this re-
ceptor in regulating other physiological processes.
Acknowledgments
We thank the midwives who consented and the patients and the
staff at labor and delivery unit for the collection of myometrial
biopsies.
Financial Support: This work was supported by a research
grant from GlaxoSmithKline to G.C.S.S. and D.S.C.-J. I.L.M.H.A.
has received salary support and a travel grant from the previous
grant. A.A.M. has received a travel grant from GlaxoSmithKline.
G.C.S.S. receives/has received research support from General
Electric andRoche. Retosiban,GSK22149A,was obtained through
a materials transfer agreement with GlaxoSmithKline.
Author Contributions: G.C.S.S. and D.S.C.-J. conceived
the study, designed the experiments, supervised the project, and
1066 Aye et al Retosiban Inhibits Myometrial Contractions J Clin Endocrinol Metab, March 2018, 103(3):1056–1067
Downloaded from https://academic.oup.com/jcem/article-abstract/103/3/1056/4774927
by University of Cambridge user
on 07 March 2018
wrote the manuscript. I.L.M.H.A. designed and performed the
experiments, analyzed the results, and wrote the manuscript.
A.A.M. assisted with tissue collections, participated in experi-
mental design, and revised the manuscript.
Correspondence and Reprint Requests: Gordon C. S.
Smith, DSc, FMedSci, Department of Obstetrics and Gynae-
cology, University of Cambridge, Rosie Hospital, Cambridge
CB2 0SW, United Kingdom. E-mail: gcss2@cam.ac.uk.
Disclosure Summary: G.C.S.S. is a named inventor in a
patent submitted by GlaxoSmithKline (UK), for the use of
retosiban to prevent preterm birth in multiple pregnancy (PCT/
EP2014/062601).D.S. is anemployeeofGlaxoSmithKline.G.C.S.S.
has been paid to attend advisory boards by GlaxoSmithKline
andRoche, andhas acted as a paid consultant toGlaxoSmithKline.
The remaining authors have nothing to disclose.
References
1. Hamilton BE,Martin JA,OstermanMJK, Curtin SC,Matthews TJ.
Births: Final Data for 2014. Hyattsville, MD: National Center for
Health Statistics; 2015.
2. Matthews TJ, MacDorman MF, Thoma ME. Infant Mortality
Statistics From the 2013 Period Linked Birth/Infant Death Data
Set. Hyattsville, MD: National Center for Health Statistics; 2015.
3. Mendelson CR. Minireview: fetal-maternal hormonal signaling in
pregnancy and labor. Mol Endocrinol. 2009;23(7):947–954.
4. Stock S, Norman J. Preterm and term labour in multiple preg-
nancies. Semin Fetal Neonatal Med. 2010;15(6):336–341.
5. HuaM, Odibo AO, Longman RE, Macones GA, Roehl KA, Cahill
AG. Congenital uterine anomalies and adverse pregnancy out-
comes. Am J Obstet Gynecol. 2011;205(6):558.e1–e5.
6. Kirkinen P, Jouppila P. Polyhydramnion: a clinical study.Ann Chir
Gynaecol. 1978;67(3):117–122.
7. Gandhi M, Fox NS. Short cervix in a patient with twin gestation.
Obstet Gynecol. 2017;130(1):47–49.
8. Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in
the human uterus during pregnancy and parturition. Am J Obstet
Gynecol. 1984;150(6):734–741.
9. Ou CW, Chen ZQ, Qi S, Lye SJ. Increased expression of the rat
myometrial oxytocin receptor messenger ribonucleic acid during
labor requires both mechanical and hormonal signals.Biol Reprod.
1998;59(5):1055–1061.
10. Terzidou V, Sooranna SR, Kim LU, Thornton S, Bennett PR,
JohnsonMR.Mechanical stretch up-regulates the human oxytocin
receptor in primary human uterine myocytes. J Clin Endocrinol
Metab. 2005;90(1):237–246.
11. Moraitis AA, Cordeaux Y, Charnock-Jones DS, Smith GC. The
effect of an oxytocin receptor antagonist (Retosiban, GSK221149A)
on the response of human myometrial explants to prolonged me-
chanical stretch. Endocrinology. 2015;156(10):3511–3516.
12. McCafferty GP, Pullen MA, Wu C, Edwards RM, Allen MJ,
Woollard PM, Borthwick AD, Liddle J, Hickey DM, Brooks DP,
Westfall TD. Use of a novel and highly selective oxytocin receptor
antagonist to characterize uterine contractions in the rat. Am J
Physiol Regul Integr Comp Physiol. 2007;293(1):R299–R305.
13. Cordeaux Y, Tattersall M, Charnock-Jones DS, Smith GC. Effects
of medroxyprogesterone acetate on gene expression in myometrial
explants from pregnant women. J Clin Endocrinol Metab. 2010;
95(12):E437–E447.
14. Borthwick AD, Liddle J. The design of orally bioavailable 2,5-
diketopiperazine oxytocin antagonists: from concept to clinical
candidate for premature labor. Med Res Rev. 2011;31(4):
576–604.
15. Cordeaux Y, Pasupathy D, Bacon J, Charnock-Jones DS, Smith GC.
Characterization of serotonin receptors in pregnant human myome-
trium. J Pharmacol Exp Ther. 2009;328(3):682–691.
16. Cordeaux Y, Missfelder-Lobos H, Charnock-Jones DS, Smith GC.
Stimulation of contractions in human myometrium by serotonin is
unmasked by smooth muscle relaxants. Reprod Sci. 2008;15(7):
727–734.
17. Van Esch E, Cline JM, Buse E,WoodCE, de Rijk EPCT,Weinbauer
GF. Summary comparison of female reproductive system in human
and the cynomolgus monkey (Macaca fascicularis).Toxicol Pathol.
2008;36(7_Suppl):171s–172s.
18. Smith GC. Use of time to event analysis to estimate the normal du-
ration of human pregnancy. Hum Reprod. 2001;16(7):1497–1500.
19. Grambsch PM, Therneau TM. Proportional hazards tests and di-
agnostics basedonweighted residuals.Biometrika. 1994;81(3):515–526.
20. Breslow N. Generalized Kruskal-Wallis test for comparing K
samples subject to unequal patterns of censorship. Biometrika.
1970;57(3):579–594.
21. LiH,HanD,HouY, ChenH, ChenZ. Statistical inferencemethods
for two crossing survival curves: a comparison of methods. PLoS
One. 2015;10(1):e0116774.
22. Peto R, Peto J. Asymptotically efficient rank invariant test pro-
cedures. J R Stat Soc Ser A-G. 1972;135:185–207.
23. Tarone RE, Ware J. Distribution-free tests for equality of survival
distributions. Biometrika. 1977;64(1):156–160.
24. Tattersall M, Cordeaux Y, Charnock-Jones DS, Smith GC. Ex-
pression of gastrin-releasing peptide is increased by prolonged
stretch of human myometrium, and antagonists of its receptor
inhibit contractility. J Physiol. 2012;590(9):2081–2093.
25. Thornton S, Miller H, Valenzuela G, Snidow J, Stier B, Fossler MJ,
Montague TH, Powell M, Beach KJ. Treatment of spontaneous
preterm labourwith retosiban: a phase 2 proof-of-concept study.Br
J Clin Pharmacol. 2015;80(4):740–749.
26. Devost D, Wrzal P, Zingg HH. Oxytocin receptor signalling. Prog
Brain Res. 2008;170:167–176.
27. Li Y, Reznichenko M, Tribe RM, Hess PE, Taggart M, Kim H,
DeGnore JP, Gangopadhyay S, Morgan KG. Stretch activates
human myometrium via ERK, caldesmon and focal adhesion sig-
naling. PLoS One. 2009;4(10):e7489.
28. Oldenhof AD, Shynlova OP, Liu M, Langille BL, Lye SJ. Mitogen-
activated protein kinases mediate stretch-induced c-fos mRNA
expression in myometrial smooth muscle cells. Am J Physiol Cell
Physiol. 2002;283(5):C1530–C1539.
29. QinY,YasudaN,AkazawaH, ItoK,KudoY, LiaoCH,Yamamoto
R, Miura S, Saku K, Komuro I. Multivalent ligand-receptor in-
teractions elicit inverse agonist activity of AT(1) receptor blockers
against stretch-induced AT(1) receptor activation. Hypertens Res.
2009;32(10):875–883.
30. Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, Woods
CE, Purcell NH, Catalucci D, Akasaka T, Bueno OF, Vlasuk GP,
Kaliman P, Bodmer R, Smith LH, Ashley E,MercolaM, Brown JH,
Ruiz-Lozano P. APJ acts as a dual receptor in cardiac hypertrophy.
Nature. 2012;488(7411):394–398.
31. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T,
MakitaN, IwanagaK,ZhuW,Kudoh S, TokoH, TamuraK, Kihara
M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I.
Mechanical stress activates angiotensin II type 1 receptorwithout the
involvement of angiotensin II. Nat Cell Biol. 2004;6(6):499–506.
32. Storch U, Mederos y Schnitzler M, Gudermann T. G protein-
mediated stretch reception. Am J Physiol Heart Circ Physiol.
2012;302(6):H1241–H1249.
33. Mederos y SchnitzlerM, Storch U,Meibers S, Nurwakagari P, Breit
A, Essin K, Gollasch M, Gudermann T. Gq-coupled receptors as
mechanosensors mediating myogenic vasoconstriction. EMBO J.
2008;27(23):3092–3103.
34. Marlow N, Wolke D, Bracewell MA, Samara M; EPICure Study
Group. Neurologic and developmental disability at six years of age
after extremely preterm birth. N Engl J Med. 2005;352(1):9–19.
doi: 10.1210/jc.2017-02195 https://academic.oup.com/jcem 1067
Downloaded from https://academic.oup.com/jcem/article-abstract/103/3/1056/4774927
by University of Cambridge user
on 07 March 2018
